Authors and Disclosures
P. Aschner,1 E. Horton,2 L. A. Leiter,3 N. Munro,4 J. S. Skyler,5 on behalf of the Global Partnership for Effective Diabetes Management*
1Javeriana University School of Medicine, Bogota, Colombia
2Joslin Diabetes Center, Boston, MA, USA
3St Michael's Hospital and University of Toronto, Toronto, ON, Canada
4Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, UK
5University of Miami and Diabetes Research Institute, Miami, FL, USA
Professor Jay S. Skyler, MD, MACP, Diabetes Research Institute, University of Miami, Miller School of Medicine, 1450 NW 10th Avenue, Suite 3054 [P.O. Box 016960 (D-110)], Miami, FL 33101-6960, USA Tel.: + 305 243 6146 Fax: + 305 243 4484 Email: email@example.com
*Global Partnership for Effective Diabetes Management Members: George Alberti, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK; Pablo Aschner, Javeriana University School of Medicine, Bogota, Colombia; Cliff Bailey, Aston University, Birmingham, UK; Lawrence Blonde, Ochsner Medical Center, New Orleans, LA, USA; Stefano Del Prato, University of Pisa, Pisa, Italy (Chair); Anne-Marie Felton, Federation of European Nurses in Diabetes, London, UK; Ramon Gomis, Hospital Clinic, Barcelona, Spain; Edward Horton, Joslin Diabetes Center, Boston, MA, USA; James LaSalle, Medical Arts Research Collaborative, Excelsior Springs, MO, USA; Hong-Kyu Lee, Seoul National University, College of Medicine, Seoul, Korea; Lawrence A. Leiter, St Michael's Hospital and University of Toronto, Toronto, ON, Canada; Stephan Matthaei, Diabetes-Center Quakenbrück, Quakenbrück, Germany; Marg McGill, Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia; Neil Munro, Beta Cell Diabetes Centre, Chelsea and Westminster Hospital, London, UK; Richard Nesto, Lahey Clinic, Burlington, MA, USA; Paul Zimmet, Baker IDI Heart and Diabetes Institute, Caulfield, Australia; Bernard Zinman, Samuel Lunefield Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Pablo Aschner: PA has received honoraries from GSK for his participation in board meetings and other related scientific activities. He has also has participated in advisory panels and provided ad hoc consultancy to Sanofi-Aventis, Merck Sharp & Dohme, Novartis and Astra-Zeneca. Edward Horton: EH has received fees for consulting and advisory boards from Abbott, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Medtronic, Merck, Metabasis, Novartis, Roche, Sanofi-Aventis, Takeda and Tethys; is on the speakers bureau for Merck and has received research support from Amylin and Eli Lilly. Lawrence A Leiter: LAL has received research funding from, has provided CME on behalf of, and/or has acted as an consultant to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Merck Schering Plough, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, Servier, and Solvay. Neil Munro: NM has received fees for serving as a speaker, a consultant or an advisory board member for Eli Lilly, Novo Nordisk, GlaxoSmithKline, Takeda, Bristol-Myers Squibb, AstraZeneca, MSD, LifeScan, Medtronic, Novartis, Pfizer, Servier, Sankio and Roche. Jay S Skyler: JSS has received research funding from Bayhill Therapeutics, Halozyme Inc., and Osiris Therapeutics Inc.; is on the Board of Directors of Amylin Pharmaceuticals, DexCom Corporation and Moerae Matrix Inc.; has received fees for serving as a consultant or an advisory board member from BD Technologies, Ideal Life, Johnson & Johnson, MannKind Corporation, Medingo Ltd., Merck, NovoNordisk, Patton Medical Devices, Salutria, sanofi-aventis, Tandem Diabetes Care, Tethys Bioscience, Teva, and Valeritas LLC.